Reuters logo
Oramed to raise $15.8 mln in direct offering to investors
December 25, 2013 / 2:10 PM / in 4 years

Oramed to raise $15.8 mln in direct offering to investors

JERUSALEM, Dec 25 (Reuters) - Oramed, an Israeli developer of oral drug delivery systems, said it had agreed to sell 1.58 million shares of its common stock at $10 per share in a registered direct offering.

Net proceeds of $15.8 million will go towards expenses primarily related to the company’s U.S. focused clinical development of its oral insulin for type 1 and type 2 diabetes indications, as well as pre clinical and clinical studies for its oral GLP-1 analog project, and for general corporate purposes, Oramed said.

Aegis Capital Corp. is acting as sole placement agent for the offering.

Oramed’s Nasdaq-listed shares closed at $15 on Tuesday.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below